Navigation Links
Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
Date:3/13/2008

utely inflamed areas, nor used to reduce the swelling of bites or stings. Hyaluronidase should not be used for intravenous injections because the enzyme is rapidly inactivated. Furosemide, the benzodiazepines, and phenytoin are incompatible with hyaluronidase. Please see accompanying package insert at http://www.hylenex.com for full Prescribing Information.

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the drug delivery, oncology and dermatology markets. The company's portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's Enhanze(TM) Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. Its key partnerships are with Roche to apply Enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets and with Baxter to apply Enhanze Technology to Baxter's biological therapeutic compound, GAMMAGARD LIQUID 10%. In addition, the company has received FDA approval for two products: Cumulase(R), for use in in-vitro fertilization, and HYLENEX, for use as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids. HYLENEX is partnered with Baxter International Inc. The Company also has a number of different enzymes in its portfolio that are targeting significant areas of unmet need.

Safe Harbor Statement

In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, (i) statements concerning the company's ability to execute on its strategy and (ii) clinical trial results and the conclusions drawn from such trials) that involve risk and uncertainties that could cause actual results to differ materially from those in the forw
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
2. Halozyme Therapeutics to Present at UBS 2007 Global Life Sciences Conference
3. Halozyme Therapeutics Reports 2007 Third Quarter Financial Results
4. Halozyme Therapeutics Amends Stockholder Rights Plan
5. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
6. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
7. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
8. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
9. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
10. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
11. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... , October 24, 2014 ... Corporation (NASDAQ: CYTR ), Vertex Pharmaceuticals Inc. ... ALXN ), Peregrine Pharmaceuticals Inc. (NASDAQ: ... research on these five companies can be accessed at: ... Thursday, October 23, 2014, ended on a positive note ...
(Date:10/22/2014)... DUBLIN , Oct. 22, 2014 ... addition of the "Global DNA Diagnostics Market ... - Size, Share, Global Trends, Company Profiles, Demand, ... 2013 - 2020" report to their offering. ... diagnostics Market (products, applications, techniques, end users and ...
(Date:10/22/2014)... October 21, 2014 Shimadzu Scientific Instruments ... data tool for the pain management and clinical markets. ... processing and review by allowing users to highlight and ... , QuantAnalytics allows analysts to filter results by ... data processing by eliminating the need to sift through ...
(Date:10/22/2014)... 22, 2014 Grace Century, a private ... projects, announces the addition of Dr. Yousef “Josh” ... advisory team. Dr. Siddiqui will provide further healthcare expertise ... graduate of University College Medical School in ... medicine in 2001. With further certification as a General ...
Breaking Biology Technology:Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 2Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 3Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 4Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 5Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 2Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 3Shimadzu Releases QuantAnalytics Open Access LCMS Software Package for Clinical Applications 2Dr. Yousef Siddiqui joins the Grace Century Advisory Team 2
... 5:00 p.m. U.S. EDT , , FRAZER, Pa., ... quarterly earnings conference call covering second quarter 2009 results for 5:00 p.m. EDT on ... , , 4:10 p.m. EDT Q2 2009 ... To participate in the conference call, dial 913-312-0379, ...
... June 30 Hospira, Inc. (NYSE: HSP ... today announced agreements with MedAssets on intravenous (I.V.) solutions ... agreement for infusion devices. The five-year MedAssets agreements are ... and equipment, and July 1, 2009, for infusion devices. ...
... needs, clinical uses and funding sources , , ROCKVILLE, ... in Rockville, Md., announced today that former Secretary of the ... board of directors. , , "I am excited ... battlefield and in emergency rooms throughout the US. I am ...
Cached Biology Technology:Hospira Announces New Contract With MedAssets for Intravenous Solutions, Renewal of Infusion Devices Agreement 2Former Secretary of Veterans Affairs James Peake to Join the Cellphire Board of Directors 2
(Date:10/18/2014)... for evaluation of suspected genetic conditions, whole-exome sequencing ... including detection of a number of rare genetic ... to a study appearing in JAMA . ... the American Society of Human Genetics annual meeting. ... regions of thousands of genes simultaneously using next-generation ...
(Date:10/17/2014)... from the University of Copenhagen have shown for the ... lungs of Cystic fibrosis patients, giving them the opportunity ... in chronic infections. , The study also discovered the ... (CF) patients was halted or slowed down by the ... all the oxygen and helped "suffocate" the bacteria, forcing ...
(Date:10/16/2014)... Washington land managers have a new synthesis of recent ... mixed-conifer (MMC) forests in the two states. , ... Eastern Oregon and Washington: A Synthesis of the Relevant ... general technical report published by the U.S. Forest Service,s ... a request from managers for a synthesis of the ...
Breaking Biology News(10 mins):Whole-exome sequencing shows potential as diagnostic tool 2Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2New report synthesizes best available science on management of moist mixed-conifer forests 2
... paradox linking artificial sweeteners such as saccharin with ... on a sweet taste has guided researchers to ... taste. , Reporting in an advance ... Chemical Senses Center describe how certain artificial sweeteners, ...
... be a key to how bacteria that infect humans ... article in the January 20 issue of the journal ... found in dirt may be the key in identifying ... infect people, predicting future clinical problems, and testing new ...
... the Kuna Indians of Panama, an international team ... is, in part, responsible, for the heart-healthy benefits ... The researchers, who are from the University of ... and Harvard Medical School, hope the findings will ...
Cached Biology News:Sweet 'water taste' paradoxically predicts sweet taste inhibitors 2Researchers use dirt to stay one step ahead of antibiotic resistance 2Researchers use dirt to stay one step ahead of antibiotic resistance 3Heart-healthy compound in chocolate identified 2
Rabbit polyclonal to GPCR G2A ( Abpromise for all tested applications). entrezGeneID: 29933 SwissProtID: Q9UNW8...
... has been developed for use with ... of nonspecific background staining due to ... blocking peroxidase with hydrogen peroxide. ... combination with additional novel components to ...
Rabbit polyclonal to Wilms Tumor Protein ( Abpromise for all tested applications). entrezGeneID: 7490 SwissProtID: P19544...
Ku80 Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Biology Products: